Investment Firms Deemed Winning Bidder to Become Exactech's New Owners

• Moving Company Forward to Emerge from Restructuring in Coming Months
• Renewing Focus on Driving Future Growth and Innovation

, /PRNewswire/ -- Exactech (or "the Company"), a global medical technology leader, this week announced a critical milestone in its restructuring process whereby a group of investors – including funds managed by Strategic Value Partners, LLC  (together with its affiliates, "SVP") and Stellex Capital Management LLC – has been designated as the winning bidder to acquire substantially all of Exactech's assets. The company is scheduled to present the sale for court approval on March 27 with closing expected in May, subject to regulatory approval, enabling the Company to successfully emerge from its restructuring process with an improved balance sheet and stronger foundation to execute its mission to be the leading surgeon partner in orthopedics and drive long-term growth.

"Since initiating the restructuring process several months ago, Exactech has continued to deliver on our commitment to develop and provide high-quality medical devices and technologies to orthopedic surgeons and patients," said Darin Johnson, Exactech President and CEO.  "We are thrilled an investor group that knows Exactech well and which recognizes the strength of our team, our surgeon relationships and our product portfolio, has been formally designated as the winning bidder. We look forward to partnering with them to strengthen our company further, drive groundbreaking advancements and enhance our ability to deliver quality products that empower surgeons and improve patient outcomes worldwide."

"Our group shares a commitment to Exactech's goals and is excited about further opportunities to drive innovation and growth," said Clara Anderson, Managing Director at SVP. "Exactech is a company with an impressive legacy of innovation, a track record of collaboration with surgeons, and an ultimate mission to improve patient lives. We deeply respect that mission, and our goal is to continue investing in and growing the business so that it can continue to provide innovative, industry-leading implants for surgeons and their patients for years to come."

The private equity and alternative asset management firms comprising the investor group collectively have more than $25 billion in assets under management and extensive operational expertise in the medical technology and device manufacturing industries. The investor group has supported Exactech through the restructuring process, including by committing over $100 million of additional financing to fund the Company's operations.

Surgeons will have the opportunity to meet representatives from the investor group at the AAOS 2025 Annual Meeting. At Booth 1729, Exactech will feature its surgeon-focused, smart technologies and implant innovations. Exactech empowers surgeons with AI-driven solutions that enhance surgical precision and patient outcomes through its Active Intelligence^® platform—a cost-effective ecosystem of smart technologies that embodies the company's approach: In Humans We Trust.

Attendees will be able to experience hands-on demonstrations of key products, including the ExactechGPS^® navigation system for knee, shoulder and ankle surgery; Predict+^® patient-specific outcome predictor*; Newton^® Knee balanced technology; and several new offerings within the Equinoxe^® Shoulder, Vantage^® Total Ankle and Truliant^® Knee Systems, as well as the Alteon®/Spartan Hip lines. Exactech's new Activit-E^® polyethylene will also be featured.

For more information, visit www.exac.com/Academy.

About Exactech 
Exactech is a global medical technology leader that empowers orthopaedic surgeons with innovative implants, surgical instruments and the Active Intelligence^® (AI) ecosystem of smart technologies to give patients EXACTLY what they need to regain mobility. Visit www.exac.com for more information and connect with us on LinkedIn, Vumedi, YouTube, Instagram and X. Exactech is represented by Ropes & Gray LLP as restructuring counsel, Riveron Management Services, LLC to provide a chief restructuring officer and additional personnel, and Centerview Partners LLC as investment banker.

About SVP
SVP is a global alternative investment firm that focuses on special situations, private equity, opportunistic credit and financing opportunities. The firm uses a combination of sourcing, financial and operational expertise to unlock value in its portfolio companies. Today SVP manages approximately $22 billion in assets under management, and since inception, has invested more than $50 billion of capital, including more than $18 billion in Europe. The firm, established by Victor Khosla in 2001, has over 200 employees, including more than 100 investment professionals, across its main offices in Greenwich (CT) and London, and a presence in Tokyo. Learn more at www.svpglobal.com.

About Stellex Capital Management
With offices in New York, Pittsburgh, Detroit, and London, Stellex Capital is a private equity firm with over $3.9 billion in assets under management. Stellex seeks to identify and deploy capital in opportunities that stand to benefit from its operationally focused and hands-on approach to investing. Portfolio companies are supported by Stellex's industry knowledge, operating capabilities, network of senior executives, strategic insights, and access to capital.

* Predict+ has not received FDA marketing authorization.

Spartan Hip Stem and Logical Cup are manufactured by Signature Orthopaedics and distributed by Exactech, Inc. The Vantage Ankle PSI is manufactured by 3D Systems, Inc., and distributed in the U.S. only by Exactech, Inc. ExactechGPS, Equinoxe Planning App and Predict+ are developed by Blue Ortho, an Exactech subsidiary, and distributed by Exactech, Inc.

SOURCE Exactech, Inc